PMID- 17217710
OWN - NLM
STAT- MEDLINE
DCOM- 20071016
LR  - 20151119
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 34
IP  - 10
DP  - 2006 Oct
TI  - [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese 
      patients with mild to moderate essential hypertension].
PG  - 877-81
AB  - OBJECTIVE: To evaluate the efficacy and safety of olmesartan medoxomil compared 
      with losartan potassium in patients with mild to moderate essential hypertension. 
      METHOD: This is a randomized, double-blind, double-dummy, active-controlled, 
      parallel, multi-center study. After a 2-week placebo run-in period, a total of 
      287 eligible subjects were randomized at 1:1 ratio to receive olmesartan 
      medoxomil 20 mg or losartan potassium 50 mg, once daily for 8 weeks. The blood 
      pressure was assessed after 4 weeks treatment. If the subject's seating diastolic 
      blood pressure (SeDBP) was still >or=90 mm Hg, the dosage was doubled for another 
      4 weeks; for those subjects whose SeDBP was <90 mm Hg after 4-week treatment, the 
      initial dosage remained unchanged and the treatment continued until completion of 
      the study. RESULTS: (1) The mean trough reduction in SeDBP from baseline in 
      olmesartan group was significantly greater than that in losartan group after 4 
      weeks (11.72 mm Hg vs 9.23 mm Hg, P=0.004) and 8 weeks treatment (12.94 mm Hg vs 
      11.01 mm Hg, P=0.035). (2) The number and percentage of responders in olmesartan 
      group (81, 65.3%) were statistically higher than those (68, 52.7%) in losartan 
      group (P=0.028) after 4 weeks treatment and were similar between the two groups 
      after 8 weeks treatment (P>0.05). (3) Individual and overall trough/peak ratios 
      of DBP and SBP in 24-hour ambulatory blood pressure monitoring were higher in 
      olmesartan group than losartan group. The hypotensive effect of olmesartan was 
      more durable than losartan at 24 hour interval. (4) The incidence of study 
      drug-related adverse events (AEs) in olmesartan group (10.5%) was similar as that 
      in losartan group (13.9%, P>0.05). Most of these AEs were mild and transient. 
      CONCLUSION: This study shows that olmesartan medoxomil, at oral dose of 20 mg-40 
      mg once daily was effective and safe for hypertension treatment and the 
      hypotensive effect was superior to losartan potassium (50 mg-100 mg once daily).
FAU - Zhu, Jun-ren
AU  - Zhu JR
AD  - Department of Cardiology, Zhong Shan Hospital, Fudan University, Shanghai 200032, 
      China. jrzhu@zshospital.com
FAU - Cai, Nai-sheng
AU  - Cai NS
FAU - Fan, Wei-hu
AU  - Fan WH
FAU - Zhu, Ding-liang
AU  - Zhu DL
FAU - He, Ben
AU  - He B
FAU - Wu, Zong-gui
AU  - Wu ZG
FAU - Ke, Yuan-nan
AU  - Ke YN
FAU - Guo, Jing-xuan
AU  - Guo JX
FAU - Ma, Hong
AU  - Ma H
FAU - Huang, Jun
AU  - Huang J
FAU - Li, Xin-li
AU  - Li XL
FAU - Chen, Yun-zhen
AU  - Chen YZ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Imidazoles)
RN  - 0 (Tetrazoles)
RN  - 6M97XTV3HD (Olmesartan Medoxomil)
RN  - JMS50MPO89 (Losartan)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/*administration & dosage
MH  - China
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy/physiopathology
MH  - Imidazoles/adverse effects/*therapeutic use
MH  - Losartan/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Olmesartan Medoxomil
MH  - Tetrazoles/adverse effects/*therapeutic use
EDAT- 2007/01/16 09:00
MHDA- 2007/10/17 09:00
CRDT- 2007/01/16 09:00
PHST- 2007/01/16 09:00 [pubmed]
PHST- 2007/10/17 09:00 [medline]
PHST- 2007/01/16 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Oct;34(10):877-81.